Influence of time to first therapy (TTFT) variable on survival outcomes of neoadjuvant chemotherapy versus upfront surgery approach in resectable pancreatic ductal adenocarcinoma

被引：0
|
作者：
Sousa, Aryanna
Pena, Paola
Kwon, Steve
机构：
[1] Roger Williams Canc Outcomes Res & Equ RWCORE Ctr, Providence, RI USA
[2] Roger Williams Med Ctr, Providence, RI USA
[3] Rush Univ Med Ctr, Chicago, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.720
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：720 / 720
页数：1
相关论文
共 50 条
  • [41] A commentary on 'The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer. A cross sectional study' - a correspondence
    Li, Xue-Lei
    Liu, Zhi-Peng
    Dai, Hai-Su
    Yin, Xian-Yu
    Chen, Zhi-Yu
    INTERNATIONAL JOURNAL OF SURGERY, 2023, 109 (12) : 4347 - 4348
  • [42] Neoadjuvant therapy versus upfront surgery for pancreatic adenocarcinoma: A propensity score matched analysis of short-term outcomes.
    Kasumova, Gyulnara G.
    de Geus, Susanna W. L.
    Tabatabaie, Omidreza
    Fadayomi, Ayotunde B.
    Miksad, Rebecca A.
    Ng, Sing Chau
    Moser, Arthur J.
    Hidalgo, Manuel M.
    Tseng, Jennifer F.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [43] Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma A Propensity Score Adjusted Analysis
    Cloyd, Jordan M.
    Chen, Hsiang-Chun
    Wang, Xuemei
    Tzeng, Ching-Wei D.
    Kim, Michael P.
    Aloia, Thomas A.
    Vauthey, Jean-Nicolas
    Lee, Jeffrey E.
    Katz, Matthew H. G.
    PANCREAS, 2019, 48 (02) : 216 - 222
  • [44] Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis
    de Geus, Susanna W. L.
    Eskander, Mariam F.
    Bliss, Lindsay A.
    Kasumova, Gyulnara G.
    Ng, Sing Chau
    Gallery, Mark P.
    Tseng, Jennifer F.
    SURGERY, 2017, 161 (03) : 592 - 601
  • [45] Defining the Optimal Duration of Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma Time for a Personalized Approach?
    Puleo, Amanda
    Malla, Midhun
    Boone, Brian A.
    PANCREAS, 2022, 51 (09) : 1083 - 1091
  • [46] Neoadjuvant chemoradiation versus surgery first for resectable pancreatic head adenocarcinoma: An economic and outcome analysis.
    Abbott, Daniel Erik
    Tzeng, Ching-Wei David
    Merkow, Ryan P.
    Cantor, Scott B.
    Katz, Matthew H. G.
    Bentrem, David J.
    Bilimoria, Karl Y.
    Crane, Christopher H.
    Varadhachary, Gauri R.
    Fleming, Jason B.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [47] Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis
    Bradley, Alison
    Van Der Meer, Robert
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [48] Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis
    Alison Bradley
    Robert Van Der Meer
    Scientific Reports, 9
  • [49] Survival benefit of neoadjuvant chemotherapy and surgery versus surgery first for resectable colorectal liver metastases: a cohort study
    Behrenbruch, Corina
    Prabhakaran, Sowmya
    Udayasiri, Dilshan
    Hollande, Frederic
    Michael, Michael
    Hayes, Ian
    Heriot, Alexander
    Knowles, Brett
    Thomson, Benjamin
    ANZ JOURNAL OF SURGERY, 2021, 91 (06) : 1196 - 1202
  • [50] Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy
    Sohei Satoi
    Hiroaki Yanagimoto
    Tomohisa Yamamoto
    Chisato Ohe
    Chika Miyasaka
    Yoshiko Uemura
    Satoshi Hirooka
    So Yamaki
    Hironori Ryota
    Taku Michiura
    Kentaro Inoue
    Yoichi Matsui
    Noboru Tanigawa
    Masanori Kon
    Surgery Today, 2017, 47 : 84 - 91
12345